Asset Details
Do you wish to reserve the book?
Airway Basal Stem Cells Inflammatory Alterations in COVID‐19 and Mitigation by Mesenchymal Stem Cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Airway Basal Stem Cells Inflammatory Alterations in COVID‐19 and Mitigation by Mesenchymal Stem Cells
Do you wish to request the book?
Airway Basal Stem Cells Inflammatory Alterations in COVID‐19 and Mitigation by Mesenchymal Stem Cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Airway Basal Stem Cells Inflammatory Alterations in COVID‐19 and Mitigation by Mesenchymal Stem Cells
2025
Overview
SARS‐CoV‐2 infection and the resultant COVID‐19 pneumonia cause significant damage to the airway and lung epithelium. This damage manifests as mucus hypersecretion, pulmonary inflammation and fibrosis, which often lead to long‐term complications collectively referred to as long COVID or post‐acute sequelae of COVID‐19 (PASC). The airway epithelium, as the first line of defence against respiratory pathogens, depends on airway basal stem cells (BSCs) for regeneration. Alterations in BSCs are associated with impaired epithelial repair and may contribute to the respiratory complications observed in PASC. Given the critical role of BSCs in maintaining epithelial integrity, understanding their alterations in COVID‐19 is essential for developing effective therapeutic strategies. This study investigates the intrinsic properties of BSCs derived from COVID‐19 patients and evaluates the modulatory effects of mesenchymal stem cells (MSCs). Through a combination of functional assessments and transcriptomic profiling, we identified key phenotypic and molecular deviations in COVID‐19 patient‐derived BSCs, including goblet cell hyperplasia, inflammation and fibrosis, which may underlie their contribution to PASC. Notably, MSC co‐culture significantly mitigated these adverse effects, potentially through modulation of the interferon signalling pathway. This is the first study to isolate BSCs from COVID‐19 patients in the Chinese population and establish a COVID‐19 BSC‐based xenograft model. Our findings reveal critical insights into the role of BSCs in epithelial repair and their inflammatory alterations in COVID‐19 pathology, with potential relevance to PASC and virus‐induced respiratory sequelae. Additionally, our study highlights MSC‐based therapies as a promising strategy to address respiratory sequelae and persistent symptoms. Airway basal stem cells derived from COVID‐19 patients demonstrated pronounced goblet cell hyperplasia, inflammatory responses and tendencies toward fibrosis. Co‐culture with mesenchymal stem cells (MSCs) notably reduced these pathological changes, likely due to MSCs' regulatory effects on the interferon signalling pathway.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Animals
/ Chronic obstructive pulmonary disease
/ COVID-19
/ Damage
/ Ethics
/ Female
/ Fibrosis
/ Humans
/ Male
/ Mesenchymal Stem Cells - cytology
/ Mesenchymal Stem Cells - metabolism
/ Mesenchymal Stem Cells - pathology
/ Mice
/ Original
/ post‐acute sequelae of COVID‐19
/ Respiratory Mucosa - pathology
